Matches in SemOpenAlex for { <https://semopenalex.org/work/W2948096323> ?p ?o ?g. }
- W2948096323 endingPage "905" @default.
- W2948096323 startingPage "905" @default.
- W2948096323 abstract "Eye cancer staging systems used for standardizing patient care and research need to be validated.To evaluate the accuracy of the eighth edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual in estimating metastatis and mortality rates of conjunctival melanoma.This international, multicenter, registry-based case series pooled data from 10 ophthalmic oncology centers from 9 countries on 4 continents. A total of 288 patients diagnosed with conjunctival melanoma from January 1, 2001, to December 31, 2013, were studied. Data analysis was performed from July 7, 2018, to September 11, 2018.Treatments included excision biopsy, cryotherapy, topical chemotherapy, radiation therapy, enucleation, and exenteration.Metastasis rates and 5-year and 10-year Kaplan-Meier mortality rates according to the clinical T categories and subcategories of the eighth edition of the AJCC Cancer Staging Manual.A total of 288 eyes from 288 patients (mean [SD] age, 59.7 [16.8] years; 147 [51.0%] male) with conjunctival melanoma were studied. Clinical primary tumors (cT) were staged at presentation as cT1 in 218 patients (75.7%), cT2 in 34 (11.8%), cT3 in 15 (5.2%), and cTx in 21 (7.3%). There were no T4 tumors. Pathological T categories (pT) were pTis in 43 patients (14.9%), pT1 in 169 (58.7%), pT2 in 33 (11.5%), pT3 in 12 (4.2%), and pTx in 31 (10.8%). Metastasis at presentation was seen in 5 patients (1.7%). Metastasis during follow-up developed in 24 patients (8.5%) after a median time of 4.3 years (interquartile range, 2.9-6.0 years). Of the 288 patients, 29 died (melanoma-related mortality, 10.1%) at a median time of 5.3 years (interquartile range, 1.8-7.0 years). The cumulative rates of mortality among patients with cT1 tumors were 0% at 1 year, 2.5% (95% CI, 0.7%-7.7%) at 5 years, and 15.2% (95% CI, 8.1%-27.4%) at 10 years of follow-up; among patients with cT2 tumors, 0% at 1 year, 28.6% (95% CI, 12.9%-58.4%) at 5 years, and 43.6% (95% CI, 19.6%-77.9%) at 10 years of follow-up; and among patients with cT3 tumors, 21.1% (95% CI, 8.1%-52.7%) at 1 year of follow-up and 31.6% (95% CI, 13.5%-64.9%) at 5 years of follow-up. Patients with cT2 and cT3 tumors had a significantly higher cumulative mortality rate compared with those presenting with cT1 tumors (log-rank P < .001). Patients with ulcerated melanomas had significantly higher risk of mortality (hazard ratio, 7.58; 95% CI, 1.02-56.32; P = .04).This multicenter, international, collaborative study yielded evidence that the conjunctival melanoma staging system in the eighth edition of the AJCC Cancer Staging Manual can be used to accurately estimate metastasis and mortality rates. These findings appear to support the use of AJCC staging as a tool for patient care and research." @default.
- W2948096323 created "2019-06-14" @default.
- W2948096323 creator A5002533106 @default.
- W2948096323 creator A5006269310 @default.
- W2948096323 creator A5012448755 @default.
- W2948096323 creator A5022187019 @default.
- W2948096323 creator A5022789539 @default.
- W2948096323 creator A5022903908 @default.
- W2948096323 creator A5026741870 @default.
- W2948096323 creator A5031144326 @default.
- W2948096323 creator A5031298664 @default.
- W2948096323 creator A5038427321 @default.
- W2948096323 creator A5038583938 @default.
- W2948096323 creator A5040651527 @default.
- W2948096323 creator A5043990028 @default.
- W2948096323 creator A5063607952 @default.
- W2948096323 creator A5069676697 @default.
- W2948096323 creator A5076162788 @default.
- W2948096323 creator A5082539797 @default.
- W2948096323 creator A5087539343 @default.
- W2948096323 date "2019-08-01" @default.
- W2948096323 modified "2023-10-17" @default.
- W2948096323 title "Multicenter, International Assessment of the Eighth Edition of the American Joint Committee on Cancer <i>Cancer Staging Manual</i> for Conjunctival Melanoma" @default.
- W2948096323 cites W1986812000 @default.
- W2948096323 cites W2030551218 @default.
- W2948096323 cites W2031045499 @default.
- W2948096323 cites W2048270011 @default.
- W2948096323 cites W2058321871 @default.
- W2948096323 cites W2077561068 @default.
- W2948096323 cites W2081062769 @default.
- W2948096323 cites W2086529225 @default.
- W2948096323 cites W2118349725 @default.
- W2948096323 cites W2439631449 @default.
- W2948096323 cites W2549229803 @default.
- W2948096323 cites W2602820028 @default.
- W2948096323 cites W2738766141 @default.
- W2948096323 cites W2767346151 @default.
- W2948096323 cites W2888633816 @default.
- W2948096323 cites W4211105541 @default.
- W2948096323 cites W4244800086 @default.
- W2948096323 cites W4292528167 @default.
- W2948096323 doi "https://doi.org/10.1001/jamaophthalmol.2019.1640" @default.
- W2948096323 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6555476" @default.
- W2948096323 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31169891" @default.
- W2948096323 hasPublicationYear "2019" @default.
- W2948096323 type Work @default.
- W2948096323 sameAs 2948096323 @default.
- W2948096323 citedByCount "34" @default.
- W2948096323 countsByYear W29480963232019 @default.
- W2948096323 countsByYear W29480963232020 @default.
- W2948096323 countsByYear W29480963232021 @default.
- W2948096323 countsByYear W29480963232022 @default.
- W2948096323 countsByYear W29480963232023 @default.
- W2948096323 crossrefType "journal-article" @default.
- W2948096323 hasAuthorship W2948096323A5002533106 @default.
- W2948096323 hasAuthorship W2948096323A5006269310 @default.
- W2948096323 hasAuthorship W2948096323A5012448755 @default.
- W2948096323 hasAuthorship W2948096323A5022187019 @default.
- W2948096323 hasAuthorship W2948096323A5022789539 @default.
- W2948096323 hasAuthorship W2948096323A5022903908 @default.
- W2948096323 hasAuthorship W2948096323A5026741870 @default.
- W2948096323 hasAuthorship W2948096323A5031144326 @default.
- W2948096323 hasAuthorship W2948096323A5031298664 @default.
- W2948096323 hasAuthorship W2948096323A5038427321 @default.
- W2948096323 hasAuthorship W2948096323A5038583938 @default.
- W2948096323 hasAuthorship W2948096323A5040651527 @default.
- W2948096323 hasAuthorship W2948096323A5043990028 @default.
- W2948096323 hasAuthorship W2948096323A5063607952 @default.
- W2948096323 hasAuthorship W2948096323A5069676697 @default.
- W2948096323 hasAuthorship W2948096323A5076162788 @default.
- W2948096323 hasAuthorship W2948096323A5082539797 @default.
- W2948096323 hasAuthorship W2948096323A5087539343 @default.
- W2948096323 hasBestOaLocation W29480963231 @default.
- W2948096323 hasConcept C121608353 @default.
- W2948096323 hasConcept C126322002 @default.
- W2948096323 hasConcept C141071460 @default.
- W2948096323 hasConcept C188261085 @default.
- W2948096323 hasConcept C2777658100 @default.
- W2948096323 hasConcept C2778527826 @default.
- W2948096323 hasConcept C2779013556 @default.
- W2948096323 hasConcept C2780149145 @default.
- W2948096323 hasConcept C2780325254 @default.
- W2948096323 hasConcept C502942594 @default.
- W2948096323 hasConcept C509974204 @default.
- W2948096323 hasConcept C71924100 @default.
- W2948096323 hasConceptScore W2948096323C121608353 @default.
- W2948096323 hasConceptScore W2948096323C126322002 @default.
- W2948096323 hasConceptScore W2948096323C141071460 @default.
- W2948096323 hasConceptScore W2948096323C188261085 @default.
- W2948096323 hasConceptScore W2948096323C2777658100 @default.
- W2948096323 hasConceptScore W2948096323C2778527826 @default.
- W2948096323 hasConceptScore W2948096323C2779013556 @default.
- W2948096323 hasConceptScore W2948096323C2780149145 @default.
- W2948096323 hasConceptScore W2948096323C2780325254 @default.
- W2948096323 hasConceptScore W2948096323C502942594 @default.
- W2948096323 hasConceptScore W2948096323C509974204 @default.
- W2948096323 hasConceptScore W2948096323C71924100 @default.
- W2948096323 hasIssue "8" @default.